Generali Investments Towarzystwo Funduszy Inwestycyjnych Crispr Therapeutics Ag Transaction History
Generali Investments Towarzystwo Funduszy Inwestycyjnych
- $157 Billion
- Q1 2025
A detailed history of Generali Investments Towarzystwo Funduszy Inwestycyjnych transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Generali Investments Towarzystwo Funduszy Inwestycyjnych holds 21,000 shares of CRSP stock, worth $798,840. This represents 0.45% of its overall portfolio holdings.
Number of Shares
21,000
Previous 19,000
10.53%
Holding current value
$798,840
Previous $748 Million
4.44%
% of portfolio
0.45%
Previous 0.43%
Shares
6 transactions
Others Institutions Holding CRSP
# of Institutions
479Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$387 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$231 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$144 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$106 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$96.6 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.97B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....